Based on promising preclinical results, a variety of TGF-beta pathway antagonists are in early phase clinical trials for the treatment of advanced cancer. However, given the complex biology of TGF-beta, the successful development of TGF-beta antagonists for cancer therapy will depend on a clear understanding of how these agents work, and the related question of how to select patients who will benefit from this type of treatment. Using a panel of 12 mouse syngeneic allograft models of metastatic breast cancer, with metastatic burden as the primary endpoint, we uncovered heterogeneous responses to TGF-beta antagonism. TGF-beta pathway blockade inhibited metastasis in some models, while having no effect on or stimulating metastasis in other models. We are continuing to apply targeted and discovery-based approaches to address molecular and biological mechanisms underlying the heterogeneity of therapeutic response and to generate useful predictive biomarkers. To do this, we have extensively characterized the panel of metastatic models with respect to genomic, transcriptomic and clinical features, and we have made this information publically available. Using this information we have shown that plausible candidate biomarkers suggested by the existing literature (eg. p53 mutation status, claudin-low tumor phenotype) do not appear to correlate with response to TGF-beta antagonism. Unexpectedly, neither TGF-beta expression levels nor extent of TGF-beta pathway activation in the primary tumor predict response to anti-TGF-beta therapy. However, tumors from models showing a desirable response to TGF-beta antagonism are characterized by transcriptomic evidence of TGF-beta pathway activation in the untreated state. Thus in vivo, the output of TGF-beta signaling may be a more sensitive indicator of the activation status of the TGF-beta pathway than any of the input parameters such as ligand levels and status of signal transduction components. We have continued to explore the mechanisms underlying the undesirable prometastatic responses to TGF-beta antagonists and we have shown that they are independent of the immune system and appear to involve disruption of direct metastasis-suppressing effects of TGF-beta on the tumor cells themselves. Analysis of in vitro responses to TGF-beta across the model panel led us to hypothesize that the metastasis-suppressing effect of TGF-beta is targeted specifically to the cancer stem cell subpopulation, and we have preliminary evidence that this is also true in vivo. We are also continuing to address ways of improving the therapeutic efficacy of TGF-beta antagonism. In one approach, we are using isoform-selective neutralizing antibodies to determine whether all three TGF-beta isoforms should be targeted for optimal response. We have generated substantial correlative data to suggest that TGF-beta1 and TGF-beta3 may play opposing roles in breast cancer. Using TGF-beta isoform-selective antibodies in preclinical mouse models, we find that sparing TGF-beta3 results in an altered metabolic profile and upregulation of genes that are associated with good prognosis in human breast cancer datasets, suggesting that this approach may have therapeutic benefit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010881-10
Application #
9556396
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Brooks, Danielle; Zimmer, Alexandra; Wakefield, Lalage et al. (2018) Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget 9:23462-23481
Hunter, Kent W; Amin, Ruhul; Deasy, Sarah et al. (2018) Genetic insights into the morass of metastatic heterogeneity. Nat Rev Cancer 18:211-223
Yang, Yuan; Yang, Howard H; Hu, Ying et al. (2017) Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget 8:30621-30643
Flanders, Kathleen C; Yang, Yu-An; Herrmann, Michelle et al. (2016) Quantitation of TGF-? proteins in mouse tissues shows reciprocal changes in TGF-?1 and TGF-?3 in normal vs neoplastic mammary epithelium. Oncotarget 7:38164-38179
Sato, Misako; Matsubara, Tsutomu; Adachi, Jun et al. (2015) Differential Proteome Analysis Identifies TGF-?-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model. PLoS One 10:e0126483
Chen, Jin-Qiu; Wakefield, Lalage M; Goldstein, David J (2015) Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics. J Transl Med 13:182
Tang, Binwu; Raviv, Asaf; Esposito, Dominic et al. (2015) A flexible reporter system for direct observation and isolation of cancer stem cells. Stem Cell Reports 4:155-69
Flanders, Kathleen C; Heger, Christopher D; Conway, Catherine et al. (2014) Brightfield proximity ligation assay reveals both canonical and mixed transforming growth factor-?/bone morphogenetic protein Smad signaling complexes in tissue sections. J Histochem Cytochem 62:846-63
Chen, Xin; Yang, Yuan; Zhou, Qiong et al. (2014) Effective chemoimmunotherapy with anti-TGF? antibody and cyclophosphamide in a mouse model of breast cancer. PLoS One 9:e85398
Wakefield, Lalage M; Hill, Caroline S (2013) Beyond TGF?: roles of other TGF? superfamily members in cancer. Nat Rev Cancer 13:328-41

Showing the most recent 10 out of 12 publications